kos pharmaceuticals inc corporate presentation pacific growth equities conference june 13 2006 safe harbor this contains forward looking statements that are intended to fall within the provisions under private securities litigation reform act several factors could cause actual events differ materially from including those listed in information certain cautionary section of company s annual report on form 10 k filed with sec for year ending dec 31 2005 and identified other reports quarterly & recent highlights q1 rapid sustainable financial net revenue increased 11 05 170 8 million was 29 197 2 if adjusted ima impact 26 4 loss per share 0 06 eps 28 imas fas 123r generated 18 7 cash operations marketable balance 437 at quarter end authorized repurchase up shares common stock excellence product commercialization cholesterol franchise trxs grew 6 trxeus cardizem la
